CSIMarket


Repligen Corp  (RGEN)
Other Ticker:  
 

Repligen Corp

RGEN's Fundamental analysis








Repligen's sales fell by -29.66 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 832

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -7.98 %

Repligen's net profit deacreased by -55.03 % in III. Quarter 2023 year on year, to $18 millions.

More on RGEN's Growth


Repligen
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 83.15 in trailing twelve-month period.
Company
77.04
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 13.32.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.12.


More on RGEN's Valuation
 
 Total Debt (Millions $) 286
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 572,464
 Net Income/Employee (TTM) $ 98,969
 Receivable Turnover (TTM) 5.63
 Tangible Book Value (Per Share $) 13.66

Repligen
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Company is currently trading with Price to Cash flow multiple of 83.15 in trailing twelve-month period.
Company
77.04
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 13.32.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.12.

Repligen Price to Book Ratio is at 4.49 lower than Indusry Avg. of 575.43. and higher than S&P 500 Avg. of 0.01

More on RGEN's Valuation

  Market Capitalization (Millions $) 8,924
  Shares Outstanding (Millions) 57
  Employees 1,170
  Revenues (TTM) (Millions $) 670
  Net Income (TTM) (Millions $) 116
  Cash Flow (TTM) (Millions $) 107
  Capital Exp. (TTM) (Millions $) -28
  Total Debt (Millions $) 286
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 572,464
  Net Income/Employee(TTM) $ 98,969
  Receivable Turnover Ratio (TTM) 5.63
  Tangible Book Value (Per Share $) 13.66

  Market Capitalization (Millions $) 8,924
  Shares Outstanding (Millions) 57
  Employees 1,170
  Revenues (TTM) (Millions $) 670
  Net Income (TTM) (Millions $) 116
  Cash Flow (TTM) (Millions $) 107
  Capital Exp. (TTM) (Millions $) -28


    RGEN's Profitability Comparisons
Repligen faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 3.41 % from 12.19 % in II. Quarter.

Repligen net profit margin of 12.87 % is currently ranking no. 11 in Biotechnology & Pharmaceuticals industry, ranking no. 88 in Healthcare sector and number 1122 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.72
  Total Debt to Equity (MRQ) 0.14
  Tangible Leverage Ratio (MRQ) 0.67
  Asset Turnover Ratio (TTM) 0.28
  Inventory Turnover Ratio (TTM) 1.52



Repligen faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 3.41 % from 12.19 % in II. Quarter.

Repligen net profit margin of 12.87 % is currently ranking no. 11 in Biotechnology & Pharmaceuticals industry, ranking no. 88 in Healthcare sector and number 1122 in S&P 500.

More on RGEN's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com